SAN FRANCISCO—After securing FDA clearance for its G7 continuous glucose monitor system last month, Dexcom is ready to begin adding the U.S. to its list of launch sites across the globe this quarter.

The Dexcom G7 continuous glucose monitor (CGM) is as accurate or better than other currently marketed CGM devices for measuring glucose in those with diabetes, new data from a pivotal study suggest.

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...